SITAZIT M ER 1000 10S

About

SITAZIT M ER 1000 is a combination oral antidiabetic medication containing Sitagliptin and Metformin (extended-release), indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body's natural ability to lower high blood glucose levels by increasing the release of insulin and decreasing the secretion of glucagon in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing glucose production in the liver, decreasing glucose absorption from the intestines, and improving insulin sensitivity in peripheral tissues.

This synergistic action helps to achieve comprehensive glycemic control, targeting multiple pathophysiological defects in type 2 diabetes. The extended-release formulation of Metformin ensures a sustained therapeutic effect and may improve gastrointestinal tolerability. SITAZIT M ER 1000 is prescribed as an adjunct to diet and exercise for adults with type 2 diabetes who require improved glycemic control, particularly when monotherapy with either agent is insufficient or when a higher dose of Metformin is needed.

Uses

• Treatment of type 2 diabetes mellitus
• Improvement of blood glucose control
• Reduction of HbA1c levels
• Used in conjunction with lifestyle modifications

Directions For Use

Take one tablet orally once daily with the evening meal, as prescribed by your doctor. Swallow the tablet whole; do not crush, chew, or break it.

Benefits

• Offers comprehensive glycemic management
• Effectively lowers both fasting and post-meal glucose
• Reduced risk of weight gain
• Sustained release for consistent action
• Improves insulin utilization
• Convenient once-daily dosing

Side Effects

• Diarrhea
• Nausea
• Abdominal discomfort
• Vomiting
• Headache
• Upper respiratory infection
• Sore throat
• Hypoglycemia (when combined with other agents)
• Pancreatitis (rare)
• Lactic acidosis (rare, Metformin)
• Joint pain
• Metallic taste

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to an increased risk of lactic acidosis, a serious complication associated with Metformin.
• Pregnancy - Consult a doctor. Generally not recommended during pregnancy; potential risks to the fetus should be discussed with a healthcare provider.
• Breastfeeding - Consult a doctor. Metformin is known to be excreted in breast milk; Sitagliptin excretion is not fully established.
• Liver - Contraindicated in severe hepatic impairment due to the increased risk of Metformin-associated lactic acidosis. Liver function should be monitored.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²). Dose adjustment is necessary for moderate impairment.
• Lung - Generally safe for lung conditions. However, conditions causing hypoxemia may increase the risk of lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.